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Low level laser therapy in patients with burning
mouth syndrome: a single blind placebo controlled
trial
M. Garrone, A. Gambino, M. Carbone, P. G. Arduino, R. Broccoletti
Department of Surgical Sciences, Oral Medicine Section, CIR-Dental School, University of Turin, Italy
Objectives. The purpose of this study was to evaluate the effectiveness of Low Level Laser Therapy (LLLT) in pa-
tients with burning mouth syndrome (BMS) and verify if the benefits on symptoms are due to placebo therapy. A fur-
ther comparison of efficacy was performed with pharmacological therapy (topical clonazepam).
Methods. The patients were divided into three therapeutic groups. The first group received LLLT with a diode laser
(980 nm, 10 Joules/cm2, 0.3 W). The second group received a placebo laser treatment. The third group was treated
topically with clonazepam for twenty-one days. The effectiveness in reducing symptoms was evaluated by compiling
the VAS (Visual Analogue Scale) scale, the McGill pain questionnaire, the PPI (Present Pain Intensity), the OHIP-49
(Oral Health Impact Profile). Moreover, the HADS (Hospital Anxiety and Depression Scale) and GDS (Geriatric Depres-
sion Scale) questionnaires evaluated the efficay of the treatment proposed regarding the anxiety-depression profile.
Results. Forty-one patients were finally analyzed (mean age 66.29 years). During the follow-up of three months, we
reported a significant improvement in pain reduction (88.2% in the laser group and 83.3% in the placebo laser group,
without a statistical significant difference); however, only the 58.3% of patients treated with clonazepam reported an
improvement. In these patients, the improvement is significant at the end of therapy. None of the treatments signifi-
cantly influenced the anxious-depressive components.
Conclusions. LLLT improves symptoms of patients with burning mouth syndrome since the first application. LLLT
seems to offer higher and more consistent therapeutic results compared to topical therapy with clonazepam.
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Objectives. The aim of the present study is to investigate the presence of proteomic signatures of Oral Squamous
Cell Carcinoma (OSCC) in saliva and their use as potential biomarkers for early and non-invasive diagnosis, as well
as prognostication.
Methods. Saliva from 45 OSCC patients and 30 healthy controls was analysed by SELDI-TOF mass spectrometry
and ProteinChip® technology. Proteomic profiles were tested with differential expression analysis and fold change of
protein peaks, principal component analysis, Spearman rank correlation test and hierarchical clustering in order to
identify a list of peaks of interest representative of controls, N- and N+ cases. Those peaks were used in a super-
vised artificial neural network in order to classify samples according to the following conditions: controls vs OSCC,
controls vs N-, and controls vs N+.
Results. When compared with controls, four peaks (i.e. 6913, 11948, 13287 and 27280 m/z) were significantly al-
tered in both N- group and N+ group; four peaks (i.e. 3353, 3433, 3482 and 4136 m/z) were selectively altered in N-
group; eight peaks were selectively altered in N+ group (i.e. 4038, 7133, 11755, 13746, 13841, 14264, 16807, 17127
m/z). Those peaks were capable to classify 100% of cases and controls, thus being potential diagnostic and prog-
nostic biomarkers for OSCC.
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Conclusions. Proteomic profiling of saliva has the potential to provide an effective tool for early diagnosis and prog-
nostication of OSCC.
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Osteonecrosis of the jaw after adjuvant endocrine
therapy plus alendronate in a breast cancer patient
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Background. Bisphosphonates-associated osteonecrosis of the jaws (BRONJ) is a serious complication, which has
been defined by Bedogni et al. (1) as an adverse drug reaction consisting of progressive destruction and death of
bone that affects the mandible and/or maxilla of patients exposed to the treatment with nitrogen-containing bisphos-
phonates (NBPs) in absence of a previous radiation treatment. Generally, IV NBPs have a strong association with
BRONJ than oral NBPs as evidenced by the higher incidence of BRONJ (0-10%) in patients treated with IV drugs
than in patients in oral therapy (<1%) (2).
Objectives. The aim of this study was to report a clinical case of BRONJ in an oncologic patient who has been treat-
ed with anastrozole and oral NBPs for secondary osteoporosis.
Case report. In February 2014 a 75-year-old woman was referred because of history of pain in the left posterior
mandibular region and hypoesthesia/anesthesia of the homolateral inferior lip and chin. In the anamnesis, she had
referred to be in therapy with alendronate since 2004, for a history of severe osteoporosis and, in multimodal
chemotherapy and anastrazole since 2010 for a diagnosis of breast cancer. Furthermore, left lower molar extraction
was performed on March 2013. Clinical examination revealed swelling of the extraoral soft tissue in the left emi-
mandible; intraorally, the presence of a mucosal fistula on the left mandibular angle was identified. CT was per-
formed and BRONJ diagnosis was defined with a stage 2A according to Bedogni et al. (1).
Conclusions. Administration of NBP is indicated to treat also osteoporosis anastrazole-induced in oncological pa-
tients, showing that patients with hormone receptor-positive early-stage breast cancer taking oral BP could represent
a subset in which it would be useful to apply BRONJ prevention protocols.
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Tooth extractions in high-risk patients previously
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Objectives. Trauma during dental surgery is the main predisposing factor for Medication Related Osteonecrosis of
the Jaws (MRONJ). Moreover, genetic factors are recognized in the pathogenesis. There are no specific guidelines
for the management of tooth extractions in patients under Bisphosphonates Therapy (BPT). 
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